Invesco Ltd. Raises Stock Position in Biohaven Ltd. (NYSE:BHVN)

Invesco Ltd. lifted its position in Biohaven Ltd. (NYSE:BHVN) by 6.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 51,814 shares of the company’s stock after purchasing an additional 3,016 shares during the period. Invesco Ltd. owned 0.05% of Biohaven worth $1,935,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of BHVN. Spire Wealth Management purchased a new stake in shares of Biohaven in the 4th quarter worth approximately $56,000. Amalgamated Bank raised its stake in Biohaven by 21.9% in the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock worth $109,000 after buying an additional 527 shares in the last quarter. US Bancorp DE lifted its holdings in Biohaven by 36.7% during the fourth quarter. US Bancorp DE now owns 2,971 shares of the company’s stock worth $111,000 after buying an additional 798 shares during the period. KBC Group NV boosted its position in Biohaven by 50.1% during the 4th quarter. KBC Group NV now owns 3,377 shares of the company’s stock valued at $126,000 after acquiring an additional 1,127 shares in the last quarter. Finally, Diversified Trust Co increased its holdings in shares of Biohaven by 16.6% in the 4th quarter. Diversified Trust Co now owns 5,585 shares of the company’s stock valued at $209,000 after acquiring an additional 795 shares during the period. Institutional investors own 88.78% of the company’s stock.

Biohaven Trading Up 0.7 %

Shares of NYSE BHVN opened at $21.89 on Wednesday. The stock has a market cap of $2.23 billion, a price-to-earnings ratio of -2.34 and a beta of 1.33. Biohaven Ltd. has a 12 month low of $15.79 and a 12 month high of $55.70. The company has a 50 day simple moving average of $25.73 and a two-hundred day simple moving average of $37.08.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.29). Analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current year.

Insider Activity at Biohaven

In other news, Director John W. Childs acquired 32,700 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was bought at an average price of $30.47 per share, with a total value of $996,369.00. Following the completion of the acquisition, the director now owns 2,320,571 shares of the company’s stock, valued at approximately $70,707,798.37. This represents a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 16.00% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on BHVN shares. Morgan Stanley dropped their price objective on Biohaven from $69.00 to $63.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. William Blair raised shares of Biohaven to a “strong-buy” rating in a research report on Thursday, April 24th. Deutsche Bank Aktiengesellschaft set a $60.00 target price on shares of Biohaven and gave the company a “buy” rating in a research report on Thursday, March 20th. JPMorgan Chase & Co. reduced their price target on Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Biohaven presently has an average rating of “Buy” and a consensus price target of $62.54.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.